Clinical-Medical Image - International Journal of Clinical & Medical Images (2022) Volume 9, Issue 6
Received: 08 June 2022, Manuscript No. ijcmi-22-66238; Editor assigned: 10 June 2022, Pre QC No. P-66238; Reviewed: 18 June 2022, QC No. Q-66238; Revised: 22 June 2022, Manuscript No. R-66238; Published: 30 June 2022, DOI: 10.4172/2376-0249.1000831
Citation: Nordli III DR, Rao CK, Gonzalez V et al. (2022) Clinical Neuroimage: Pediatric Gliomatosis Cerebri. Int J Clin Med Imaging 9:831.
Copyright: © 2022 Nordli III DR, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
A 16-year-old previously-healthy young man presented to the pediatric emergency department with 5 weeks of stepwise neurologic complaints: orobuccal weakness followed by diplopia, dysarthria, and impaired coordination. His neurologic exam showed left appendicular ataxia, right ptosis, and right hemifacial plegia. Empiric immunotherapy trial with glucocorticoids yielded minimal symptomatic improvement and autoimmune testing was negative. Temporal biopsy confirmed diffuse high-grade H3- and IDH-wild-type glioma.
Gliomatosis cerebri is a growth pattern by definition involving three or more lobes of the brain [1,2]. Imaging can resemble cortical encephalitis and may not show contrast enhancement [1,2]. A lack of response to conventional immunotherapy should raise concerns for gliomatosis cerebri in pediatric patients being treated for autoimmune encephalitis [1,2] (Figures 1 and 2).
Gliomatosis Cerebri, Autoimmune encephalitis
No funding was secured for this study.
Emilie G (2016) Pediatric gliomatosis cerebri: A review of 15 Years. J Child Neurol 31(3): 378-387.
Taillibert S (2006) Gliomatosis cerebri: A review of 296 cases from the ANOCEF database and the literature. J Neurooncol 76(2): 201-205.